Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery.

Woude, H. J. van der; Bloem, Johan L.; Verstraete, Koenraad; Taminiau, A. H. M.; Nooy, M. A.; Hogendoorn, Pancras C.W.

doi:10.2214/ajr.165.3.7645476

Cited by 170 publications

(82 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ability of DCE-MR imaging to monitor the response to chemotherapy allows for the early detection of treatment failure, rapid institution of a treatment strategy change, and the potential for improved patient outcomes. 17,18 This ability is important in light of the approximate 2.5%-11% recurrence rate seen in spinal metastases. 22 In addition, as van der Woude et al 17 showed, DCE-MR imaging is able to detect viable tumor areas before surgical resection.…”

Section: Discussionmentioning

confidence: 99%

“…17,18 This ability is important in light of the approximate 2.5%-11% recurrence rate seen in spinal metastases. 22 In addition, as van der Woude et al 17 showed, DCE-MR imaging is able to detect viable tumor areas before surgical resection.…”

Section: Discussionmentioning

confidence: 99%

“…8,9 Furthermore, the ability of DCE-MR imaging to monitor tumor response to chemotherapy and radiation, as well as to detect areas of viable tumor before resection, has also been described. 17,18 The potential role for DCE-MR imaging to differentiate between various types of metastatic lesions, however, has not yet been studied. An ability to do so would help to noninvasively narrow the differential for potential primary tumor sites, to individualize treatment, and to better predict prognostic outcomes.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Characterizing Hypervascular and Hypovascular Metastases and Normal Bone Marrow of the Spine Using Dynamic Contrast-Enhanced MR Imaging

Khadem¹,

Karimi²,

Peck³

et al. 2012

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Characterizing Hypervascular and Hypovascular Metastases and Normal Bone Marrow of the Spine Using Dynamic Contrast-Enhanced MR Imaging

Khadem¹,

Karimi²,

Peck³

et al. 2012

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

“…nodular fascitis, schwannomas etc.) and malignant lesions, dynamic contrast-enhanced MR imaging seems to be a promising technique in distinguishing benign from malignant soft tissue tumors [15]. Early, rapidly progressive and peripheral enhancement favor the diagnosis of soft tissue malignancy, whereas late and gradual or absent dynamic enhancement more likely occurs in benign lesions.…”

Section: Contrast-enhanced Mr Imagingmentioning

confidence: 99%

Imaging Spectrum in Soft Tissue Sarcomas

Aga

Singh

Parihar

et al. 2011

Indian J Surg Oncol

View full text Add to dashboard Cite

Imaging plays an important role in detection, diagnosis as well as pre and post operative management of patients with soft tissue sarcomas. Soft tissue sarcomas are generally a diagnostic dilemma needing the complimentary use of both radiology and pathology for their accurate diagnosis. In this review article, we have tried to highlight the important facts about the various imaging modalities available as well as the recent advances in the field of radiology.

show abstract

“…These include neoadjuvant chemotherapy in bladder and breast cancers and bone sarcomas (37)(38)(39)(40). In general, these studies have shown that there is a progressive decrease in MR parameters such as enhancement or K trans which is associated with a decrease in tumor size following chemotherapy and that an increase or no change in such parameters is seen in those patients with progressive disease (40,41).…”

Section: Use Of Dce-mri As a Pharmacodynamic Endpoint For Other Anti-mentioning

confidence: 99%

MR in oncology drug development

Galbraith

2006

NMR Biomed.

View full text Add to dashboard Cite

This article reviews the use of MR in preclinical and clinical experiments to aid drug development. In particular it concentrates on the use of MR to study tumor microvasculature following treatment with anti-vascular agents and the use of MRS to study tumor metabolism following treatment with a variety of anti-cancer agents. The advantages and disadvantages of a variety of techniques including contrast-and noncontrast-enhanced methods are discussed and the data from clinical trials using these techniques are reviewed. Despite the consensus documents produced to date for both dynamic contrastenhanced MRI and MRS, most of the trials reported used alternative methods, and different nomenclature for the MR parameters used. This continues to inhibit the comparison between novel therapeutics and between different trials with the same compound. Comprehensive data from multicenter trials on the reproducibility of techniques is still lacking in the literature and the implications of the available data on clinical trial design is also discussed.

show abstract

Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery.

Cited by 170 publications

References 2 publications

Characterizing Hypervascular and Hypovascular Metastases and Normal Bone Marrow of the Spine Using Dynamic Contrast-Enhanced MR Imaging

Characterizing Hypervascular and Hypovascular Metastases and Normal Bone Marrow of the Spine Using Dynamic Contrast-Enhanced MR Imaging

Imaging Spectrum in Soft Tissue Sarcomas

MR in oncology drug development

Contact Info

Product

Resources

About